Bayer: Thromboembolism trials

The registry lists 15 Thromboembolism studies with Bayer as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 2Phase 3 5No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rivaroxaban for Treatment in Venous or Arterial Thrombosis in NeonatesCompletedNCT02564718Phase 1/2Results posted
• Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)TerminatedNCT02313909Phase 3Results posted
• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)CompletedNCT02064439Phase 3Results posted
• Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for CardioversionCompletedNCT01674647Phase 3Results posted
• A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese ParticipantsCompletedNCT06619483Phase 1
• A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 YearsCompletedNCT06562985Phase 1
• A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male ParticipantsCompletedNCT04720092Phase 1
• Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic AcidCompletedNCT03746275
• Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care TherapyCompletedNCT02210819
• Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial FlutterCompletedNCT01839357Phase 3
• Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care TherapyCompletedNCT01619007
• Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)WithdrawnNCT01523418
• SALTO - Epidemiological Study on Compliance and Treatment SatisfactionCompletedNCT00911001
• ODiXahip - a Phase IIa Dose Escalating Proof of Principle TrialCompletedNCT00839826Phase 2
• Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to EnoxaparinCompletedNCT00329628Phase 3